Moneycontrol PRO

you are here: HomeNewscoronavirus3-Point Analysis | Why is Bharat Biotech’s ‘Covaxin’ receiving backlash post approval?

SHOW NAMES

X

coronavirus

3-Point Analysis | Why is Bharat Biotech’s ‘Covaxin’ receiving backlash post approval?

The Drug Controller General of India (DCGI) on January 3 granted permission for restricted emergency use of the AstraZeneca-Oxford University and Bharat Biotech Covid-19 vaccines. The approval was based on the recommendations of the Subject Expert Committee (SEC), which reviewed the data on safety and immunogenicity of the two vaccines. However, post the announcement it is India’s indigenous vaccine which has found itself in the middle of a controversy. Here’s why.

first published: Jan 4, 2021 06:46 pm

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347